Updated Jul 16, 2026
Haddadin Yezan Munther has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $39K.
Yezan Munther Haddadin is a corporate executive currently serving as a Director at Outlook Therapeutics, Inc. His involvement in the biotechnology sector suggests a focus on therapeutic innovations.
| Role | Director |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | OTLK | Outlook Therapeutics, Inc. | P — Open-market purchase | 29.0K | $0.83 | $24K |
| 2026-05-27 | OTLK | Outlook Therapeutics, Inc. | P — Open-market purchase | 34.0K | $0.44 | $15K |
Yezan Munther Haddadin is a corporate executive currently serving as a Director at Outlook Therapeutics, Inc. His involvement in the biotechnology sector suggests a focus on therapeutic innovations.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 2 open-market purchases ($39K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Haddadin Yezan Munther profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.